Sabra Khalid Salim

Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary A major challenge with immunotherapies, including those for glioblastoma, is the limited number of tumor-specific targets for the immune system to focus on; other targets may be enriched on tumor cells, but they run the risk of on-target, off-tumor effects. Here, Maich et al.

Anido J. Sáez-Borderías A. Gonzàlez-Juncà A. Rodón L. Folch G. Carmona M.A. Prieto-Sánchez R.M. Barba I. Martínez-Sáez E. Prudkin L. et al. TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell. 2010; 18: 655-668 Arndt K. Grinenko T. Mende N. Reichert D. Portz M. Ripich T. Carmeliet P. Corbeil D. Waskow C. CD133 is a modifier of hematopoietic progenitor frequencies but is dispensable for the maintenance of mouse hematopoietic stem cells. Proc.